KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for Adaptive Biotechnologies (ADPT) over the last 6 years, with Q3 2025 value amounting to $286.3 million.

  • Adaptive Biotechnologies' Total Non-Current Liabilities fell 1450.38% to $286.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $286.3 million, marking a year-over-year decrease of 1450.38%. This contributed to the annual value of $336.9 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Total Non-Current Liabilities of $286.3 million as of Q3 2025, which was down 1450.38% from $317.1 million recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Total Non-Current Liabilities peaked at $343.4 million during Q2 2024, and registered a low of $240.4 million during Q2 2023.
  • Moreover, its 4-year median value for Total Non-Current Liabilities was $301.7 million (2025), whereas its average is $295.9 million.
  • Per our database at Business Quant, Adaptive Biotechnologies' Total Non-Current Liabilities soared by 4285.08% in 2024 and then crashed by 1450.38% in 2025.
  • Over the past 4 years, Adaptive Biotechnologies' Total Non-Current Liabilities (Quarter) stood at $267.2 million in 2022, then fell by 10.01% to $240.4 million in 2023, then skyrocketed by 40.13% to $336.9 million in 2024, then decreased by 15.0% to $286.3 million in 2025.
  • Its Total Non-Current Liabilities was $286.3 million in Q3 2025, compared to $317.1 million in Q2 2025 and $320.6 million in Q1 2025.